Monopar Therapeutics Inc. became the latest biotech company to join the Helix 51 biomedical incubator community at Rosalind Franklin University of Medicine and Science, as announced on January 23, 2025. Monopar will utilize the labs and other resources available at Helix 51 to advance its research objectives.
Helix 51 is the only wet-and dry-lab based incubator in Lake County, Illinois, providing a specialized environment for biotech and biopharma companies. Monopar's COO, Andrew Cittadine, stated that joining the vibrant biomedical community at RFU presents an opportunity to accelerate the development of new products.
This move is expected to support Monopar's pipeline, which includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and the late-stage ALXN1840 for Wilson Disease. The university's Innovation and Research Park also offers additional research support and expertise.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.